Melanoma Trial Landscape (October 2026)

Last updated: Oct 15, 2026 · Built by a patient who got tired of scrolling ClinicalTrials.gov

Overview

Active interventional trials with status RECRUITING or NOT_YET_RECRUITING. A multi-phase trial (e.g. 1/2) is counted in each of its phases.

Mechanism Breakdown

Recruiting trials grouped by drug class. Trials with unclassifiable or non-therapeutic interventions are excluded from this view.

Recently Updated Trials

NCT	Phase	Title	Mechanism
NCT05136196	2	BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study	Multiple kinases -- multi-kinase inhibitor (Cabozantinib); PD-1 -- immune checkpoint inhibitor (Nivolumab)
NCT05896839	1, 2	Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer	CTLA-4 + PD-1 -- immune checkpoint inhibitors (monoclonal antibodies) + mTOR -- inhibitor + corticosteroid
NCT07574047	2	MELCHRONO: A Prospective Randomized Study Investigating Chrono-immunotherapy for Advanced Melanoma.	Immune checkpoints -- immune checkpoint inhibition (monoclonal antibodies)
NCT06596915	1	Safety and Efficacy of BA1302 in Patients With Advanced Solid Tumors	Unknown mechanism
NCT06319196	2	Clear Me: Interception Trial to Detect and Clear Molecular Residual Disease in Patients With High-risk Melanoma	LAG-3 + PD-1 -- bispecific antibody (Opdualag)

Top Sponsors

Sponsor	Recruiting trials
M.D. Anderson Cancer Center	18
Vastra Gotaland Region	7
National Cancer Institute (NCI)	6
Xijing Hospital	5
Peking University Cancer Hospital & Institute	5

Geographic Distribution

Countries/regions with the most active trial sites for melanoma. A multi-site trial is counted once per country/region.

Emerging Classes

Phase-1 trials whose listed start date falls within the last 12 months — the leading edge of the field.

Start	NCT	Title	Mechanism
Jun 30, 2027	NCT06739226	Combination Immunotherapy Targeting Melanoma	Tumor antigens -- CAR T cells, cytotoxic T lymphocytes, and dendritic cell vaccine
Jan 31, 2027	NCT05903937	Locoregional Administration of TIL and Lymphodepletion in Patients With Melanoma and Liver Metastases	Tumor infiltrating lymphocytes (TIL) -- adoptive cell therapy + alkylating agent (melphalan) + IL-2 -- cytokine
Jan 2027	NCT07183852	Locoregional or Systemic Administration of Autologous Tumor Infiltrating Lymphocytes in Patients With Metastatic Melanoma	Tumor-infiltrating lymphocytes + melphalan + IL-2 -- adoptive cell therapy + chemotherapy + cytokine
Nov 1, 2026	NCT07817901	Phase 1b/2 Clinical Trial to Evaluate the Safety and Efficacy of Combination Therapy With Pembrolizumab and Irinotecan in Patients With Metastatic or Recurrent Malignant Melanoma	PD-1 -- immune checkpoint inhibitor (monoclonal antibody) + Topoisomerase I -- enzyme inhibitor (chemotherapy)
Nov 1, 2026	NCT07838974	Adding Anakinra and Tocilizumab to Nivolumab and Ipilimumab for the Treatment of Melanoma Patients 50 Years of Age or Older	IL-1 receptor + IL-6 receptor + PD-1 + CTLA-4 -- receptor antagonists and immune checkpoint inhibitors (biologicals)
Oct 31, 2026	NCT07631325	Axelopran and Nivolumab in PD-1-Refractory Metastatic Melanoma	Opioid receptors -- antagonist (small molecule)
Oct 1, 2026	NCT07700121	PICSTAT Pilot Study for CD8 PET/CT-Guided Lifileucel Treatment in Advanced Melanoma	Tumor-infiltrating lymphocytes (TILs) -- adoptive cell therapy
Oct 2026	NCT07281924	Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis	PD-1 + LAG-3 -- bispecific antibody (Nivolumab and Relatlimab); Melphalan -- alkylating agent

Source: ClinicalTrials.gov, synced daily. Aggregated by ClinTrialFinder.